



# SAFETY DATA SHEET

Revision date: 01-Mar-2015

Version: 3.0

Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

**Trade Name:** ZITHROMAX®, Azitromicina; Zitromax  
**Synonyms:** Azithromycin dihydrate single dose packet  
**Chemical Family:** Azalide

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as antibiotic agent

### Details of the Supplier of the Safety Data Sheet

**Pfizer Inc**  
**Pfizer Pharmaceuticals Group**  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

**Pfizer Ltd**  
**Ramsgate Road**  
**Sandwich, Kent**  
**CT13 9NJ**  
**United Kingdom**  
**+00 44 (0)1304 616161**

**Emergency telephone number:**  
**CHEMTREC (24 hours): 1-800-424-9300**  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours): +1-703-527-3887**

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

**GHS - Classification** Not classified as hazardous

### US OSHA Specific - Classification

**Physical Hazard:** Combustible Dust

### EU Classification:

EU Indication of danger: Not classified

### Label Elements

**Hazard Statements:** May form combustible dust concentrations in air

### Other Hazards

No data available

### Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

Page 2 of 9

Revision date: 01-Mar-2015

Version: 3.0

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

**Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Azithromycin dihydrate	117772-70-0	Not Listed	Not Listed	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*
Silicon dioxide, colloidal NF	7631-86-9	231-545-4	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Spray dried artificial banana flavor	MIXTURE	Not Listed	Not Listed	Not Listed	*
Spray dried artificial cherry flavor	MIXTURE	Not Listed	Not Listed	Not Listed	*
Sodium phosphate tribasic, anhydrous	7601-54-9	231-509-8	Not Listed	Not Listed	*

**Additional Information:**

\* Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

- Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture**

- Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.
- Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

Revision date: 01-Mar-2015

Page 3 of 9

Version: 3.0

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Azithromycin dihydrate

Pfizer OEL TWA-8 Hr: 500µg/m<sup>3</sup>

#### Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Estonia OEL - TWA	10 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
Latvia OEL - TWA	5 mg/m <sup>3</sup>
Lithuania OEL - TWA	10 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet  
Revision date: 01-Mar-2015

Page 4 of 9

Version: 3.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Slovakia OEL - TWA	6 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
<b>Silicon dioxide, colloidal NF</b>	
Australia TWA	2 mg/m <sup>3</sup>
Austria OEL - MAKs	4 mg/m <sup>3</sup>
	0.3 mg/m <sup>3</sup>
Czech Republic OEL - TWA	0.1 mg/m <sup>3</sup>
	4.0 mg/m <sup>3</sup>
Estonia OEL - TWA	2 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	4 mg/m <sup>3</sup>
Germany (DFG) - MAK	4 mg/m <sup>3</sup>
Ireland OEL - TWAs	6 mg/m <sup>3</sup>
	2.4 mg/m <sup>3</sup>
Latvia OEL - TWA	1 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m <sup>3</sup>
Switzerland OEL -TWAs	4 mg/m <sup>3</sup>
	0.3 mg/m <sup>3</sup>

<b>Analytical Method:</b>	Analytical method available for Azithromycin. Contact Pfizer Inc for further information.
<b>Exposure Controls</b>	
<b>Engineering Controls:</b>	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
<b>Personal Protective Equipment:</b>	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
<b>Hands:</b>	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
<b>Eyes:</b>	Wear safety glasses or goggles if eye contact is possible.
<b>Skin:</b>	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
<b>Respiratory protection:</b>	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Powder	<b>Color:</b>	White to off-white
<b>Odor:</b>	Cherry-banana	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture
<b>Solvent Solubility:</b>	No data available		
<b>Water Solubility:</b>	No data available		
<b>pH:</b>	No data available.		
<b>Melting/Freezing Point (°C):</b>	No data available		
<b>Boiling Point (°C):</b>	No data available.		
<b>Partition Coefficient: (Method, pH, Endpoint, Value)</b>			
<b>Silicon dioxide, colloidal NF</b>			
No data available			

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

Page 5 of 9

Revision date: 01-Mar-2015

Version: 3.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Sucrose

No data available

#### Spray dried artificial banana flavor

No data available

#### Spray dried artificial cherry flavor

No data available

#### Sodium phosphate tribasic, anhydrous

No data available

#### Azithromycin dihydrate

Measured 7 Log P 0.67

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

#### Flammability:

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available. This material may present a dust explosivity hazard and has moderate sensitivity to ignition

**Min. Ignition Energy (mJ):** 10-25

**Polymerization:** Will not occur

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

#### Possibility of Hazardous Reactions

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** May cause irritation (based on animal data) . Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

**Known Clinical Effects:** May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### Sucrose

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

Page 6 of 9

Revision date: 01-Mar-2015

Version: 3.0

### 11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 29.7 g/kg

#### Azithromycin dihydrate

Mouse (F) Oral LD50 4000 mg/kg

Mouse (M) Oral LD50 3000mg/kg

Rat Oral LD50 > 2000mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Azithromycin dihydrate

Antigenicity- Active anaphylaxis Guinea Pig Negative

Antigenicity- Passive cutaneous anaphylaxis Rabbit Negative

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Azithromycin may be slightly irritating to eyes, based on extrapolation of minimal and moderate irritation seen in intravenous and intramuscular irritation studies, respectively.

**Skin Irritation / Sensitization** Azithromycin may be slightly irritating to skin, based on extrapolation of minimal and moderate irritation seen in intravenous and intramuscular irritation studies, respectively.

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Azithromycin dihydrate

6 Month(s) Rat Oral 10 mg/kg/day LOEL Liver

6 Month(s) Dog Oral 10 mg/kg/day LOEL Liver

1 Month(s) Rat Intravenous 5 mg/kg/day NOEL Liver

1 Month(s) Dog Intravenous 5 mg/kg/day NOEL Liver

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Azithromycin dihydrate

Reproductive & Fertility Rat Oral 10 mg/kg/day NOEL Fertility

Prenatal & Postnatal Development Mouse Oral 40 mg/kg/day NOEL Not Teratogenic

Prenatal & Postnatal Development Rat Oral 40 mg/kg/day NOEL Not Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

##### Azithromycin dihydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vivo* Cytogenetics Mouse Lymphoma Negative

*In Vitro* Cytogenetics Mouse Negative

*In Vitro* Cytogenetics Human Lymphocytes Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### **Silicon dioxide, colloidal NF**

**IARC:** Group 3 (Not Classifiable)

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet

Revision date: 01-Mar-2015

Page 7 of 9

Version: 3.0

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** In the environment, the active ingredient in this formulation is expected to mainly reside in the aquatic environment and slowly degrade.

#### Toxicity:

##### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

###### **Azithromycin dihydrate**

*Daphnia magna* (Water Flea) OECD EC50 48 Hours 120 mg/L  
*Hyallela azteca* (Freshwater Amphipod) OECD LC50 96 Hours > 120 mg/L  
*Oncorhynchus mykiss* (Rainbow Trout) OECD LC50 96 Hours > 84 mg/L  
Green Algae OECD EC50 72 Hours 0.0037 mg/L  
*Microcystis aeruginosa* (Blue-green Alga) OECD ErC50 96 Hours 0.0018 mg/L

##### Bacterial Inhibition: (Inoculum, Method, End Point, Result)

###### **Azithromycin dihydrate**

*Aspergillus niger* (Fungus) OECD MIC > 1000 mg/L  
*Trichoderma viride* (Fungus) OECD MIC > 1000 mg/L  
*Clostridium perfringens* (Bacterium) OECD MIC 2.0 mg/L  
*Bacillus subtilis* (Bacterium) OECD MIC2.0 mg/L

##### Terrestrial Toxicity: (Species, Method, End Point, Duration, Result)

###### **Azithromycin dihydrate**

*Eisenia foetida* (Earthworm) TAD NOEC 28 Days 1000 mg/kg

###### **Azithromycin dihydrate**

*Pimephales promelas* (Fathead Minnow) OECD 32 Day(s) NOEC 4.6 mg/L Survival  
*Ceriodaphnia dubia* (Daphnids) OPPTS 7 Day(s) NOEC 0.0044 mg/L Reproduction

**Persistence and Degradability:** No data available

#### **Bio-accumulative Potential:**

##### **Partition Coefficient: (Method, pH, Endpoint, Value)**

###### **Azithromycin dihydrate**

Measured 7 Log P 0.67

**Mobility in Soil:** No data available

## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet  
Revision date: 01-Mar-2015

Page 8 of 9

Version: 3.0

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

#### **Azithromycin dihydrate**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### **Spray dried artificial banana flavor**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### **Spray dried artificial cherry flavor**

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### **Sodium phosphate tribasic, anhydrous**

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg



## SAFETY DATA SHEET

Material Name: Zithromax®(Azithromycin dihydrate) for oral suspension, single dose packet  
Revision date: 01-Mar-2015

Page 9 of 9

Version: 3.0

### 15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-509-8

#### Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

#### Silicon dioxide, colloidal NF

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

### 16. OTHER INFORMATION

**Data Sources:** Pfizer proprietary drug development information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 12 - Ecological Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

**Revision date:** 01-Mar-2015  
Product Stewardship Hazard Communication

**Prepared by:** Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**